UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results

Calcagni, G; Limongelli, G; D'Ambrosio, A; Gesualdo, F; Digilio, MC; Baban, A; Albanese, SB; ... Marino, B; + view all (2017) Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. International Journal of Cardiology , 245 pp. 92-98. 10.1016/j.ijcard.2017.07.068. Green open access

[thumbnail of Kaski_Cardiac_morbidity_and_mortality_in_RASopathies_calcagni_IJC_2017_1470R1.pdf]
Preview
Text
Kaski_Cardiac_morbidity_and_mortality_in_RASopathies_calcagni_IJC_2017_1470R1.pdf - Accepted Version

Download (78kB) | Preview

Abstract

BACKGROUND: RASopathies are developmental disease caused by mutations in genes encoding for signal transducers of the RAS-MAPK cascade. The aim of the present study was to provide a comprehensive description of morbidity and mortality in patients with molecularly confirmed RASopathy. METHODS: A multicentric, observational, retrospective study was conducted in seven European cardiac centres participating to the CArdiac Rasopathy NETwork (CARNET). Clinical records of 371 patients with confirmed molecular diagnosis of RASopathy were reviewed. Mortality was described as crude mortality, cumulative survival and restricted estimated mean survival. Multivariable regression analysis was used to assess the impact of mutated genes on number of interventions and overall prognosis. RESULTS: Cardiac defects occurred in 80.3% of cases, almost half of them underwent at least one intervention. Overall, crude mortality was 0.29/100 patients-year. Cumulative survival was 98.8%, 98.2%, 97.7%, 94.3%, at 1, 5, 10, and 20 years, respectively. Restricted estimated mean survival at 20 years follow-up was 19.6 years. Ten patients died (2.7% of the entire cohort; 3.4% of patients with cardiac defect). Patients with hypertrophic cardiomyopathy (HCM) and age < 2 years or young adults, as well as subjects with biventricular obstruction and PTPN11 mutations had a higher risk of cardiac death. CONCLUSIONS: The risk of intervention was higher in individuals with Noonan syndrome and pulmonary stenosis carrying PTPN11 mutations. Overall, mortality was relatively low, even though the specific association between HCM, biventricular outflow tract obstructions and PTPN11 mutations appeared to be associated with early mortality, including immediate post-operative events and sudden death.

Type: Article
Title: Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ijcard.2017.07.068
Publisher version: https://doi.org/10.1016/j.ijcard.2017.07.068
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Noonan syndrome, RASopathies, Congenital heart defect, Children, Hypertrophic cardiomyopathy
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
URI: https://discovery.ucl.ac.uk/id/eprint/10062088
Downloads since deposit
132Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item